Drug intelligence / Profile preview

antisense microRNA-141

Development stage
Preclinical
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Parenteral, Subcutaneous, Intrathecal, Intracerebroventricular
01

Overview

Antisense microRNA-141 (also known as anti-miR-141 or antagomir-141) is a synthetic oligonucleotide designed to bind and sequester mature microRNA-141 (miR-141). miR-141 is a member of the miR-200 family and typically acts as a tumor suppressor in various cancers, including colorectal cancer, by targeting genes involved in the epithelial-mesenchymal transition (EMT) such as ZEB1 and ZEB2. By inhibiting miR-141, these antisense molecules lead to the upregulation of its target genes, which in experimental models of colorectal cancer has been shown to promote cell proliferation, migration, and activation of the HGFR (c-MET) pathway. While primarily used as a research tool to study miR-141 function, antisense oligonucleotides targeting microRNAs are being explored as potential therapeutic agents.

Other names
antisense miR-141microRNA-141 inhibitormicroRNA141 inhibitormicroRNA 141 inhibitor
02

Targets

miR-141 (MicroRNA-141)

Beyond the preview

Go deeper on antisense microRNA-141.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on antisense microRNA-141.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call